Searchable abstracts of presentations at key conferences on calcified tissues

ba0007oc24 | (1) | ICCBH2019

TA-46, a recombinant soluble FGFR3 receptor for the treatment of achondroplasia, is safe and well-tolerated in healthy volunteers

Collins Samuel , Greig Gerard , Porter Richard , Stavenhagen Jeff , Santarelli Luca , Meyer Christian

Objectives: To assess the safety, tolerability and pharmacokinetic (PK) profile of single and multiple doses of TA-46 administered subcutaneously to healthy volunteers.Methods: This was a double-blind, randomized, placebo-controlled trial in a total of 72 subjects. Cohorts of 8 subjects were randomised to receive either TA-46 or placebo in a 3:1 ratio in single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. SAD doses were 0.3, 1, 3, 10 a...

ba0007p67 | (1) | ICCBH2019

Bone health outcomes in children and adolescents with neuromuscular disease

Biggin Andrew , Chua Verene , Wall Christie , Pacey Verity , Gray Kelly , McGee Richard , Poon Myra , Munns Craig

Objectives: To compare and contrast the natural history of osteoporosis and response to zoledronate in children and adolescents with Duchene muscular dystrophy (DMD), spinal muscular atrophy (SMA) or other congenital muscular dystrophies (CMD).Methods: A retrospective medical record review of fracture history, treatment and bone mineral densitometry of children managed at a tertiary centre in Sydney over the last 6 years.Results: A...

ba0007p148 | (1) | ICCBH2019

Management of foramen magnum stenosis in patients with achondroplasia: relative merit of clinical and radiological indications for foramen magnum decompression

Almeida Timoteo , Singleton William , Monsell Fergal , Smithson Sarah , Edwards Richard , Burren Christine

Introduction: Achondroplasia, the commonest skeletal dysplasia, is caused by specific variant(s) in the fibroblast growth factor receptor 3 (FGFR3) gene that cause abnormal spine, skull and limb bone growth. Surgical indications for foramen magnum stenosis in this population vary widely in the literature.Methods: We performed a retrospective analysis of patients with achondroplasia aged >20 years (n=33) in our regional skeletal dysplasia cli...

ba0007p163 | (1) | ICCBH2019

Prenatal oligohydramnios is associated with hip shape in adolescent males

Tobias Jon , Frysz Monika , Lawlor Debbie , Aspden Richard , Gregory Jennifer , Ireland Alex

Hip development is influenced by mechanical loading during fetal movement by joint and reaction forces equivalent to several times bodyweight. These forces increase with fetal size and gestation length, and are lower in oligohydramnios and breech presentation which are both risk factors for developmental hip disorders. However, associations between indicators of prenatal mechanical loading and hip shape in later life remain unexplored. We therefore examined associations betwee...

ba0007p188 | (1) | ICCBH2019

Impact of type 1 diabetes mellitus on skeletal integrity and strength in adolescents aged 12 to 16 years; as assessed by High Resolution peripheral Quantitative Computed Tomography (HRpQCT)

Devaraja Janani , Dimitri Paul , Paggiosi Margaret , Clark Carolyn , Jacques Richard , Bishop Nick

Objectives: To investigate the impact of Type 1 Diabetes Mellitus (T1DM) on cortical and trabecular microarchitecture, and bone strength in adolescents; using High Resolution peripheral Quantitative Computed Tomography (HRpQCT) and microfinite element analysis. To our knowledge, this is the first study in children, assessing the impact of T1DM on skeletal microstructure and strength using HRpQCT.Methods: We recruited 22 patients aged 12–16 years wit...

ba0007p199 | (1) | ICCBH2019

Diversity of outcomes in randomised trials of interventions for children with osteogenesis imperfecta

McGee Richard , Wall Christie-Lee , Biggin Andrew , Pacey Verity , Poon Myra , Munns Craig

Objective: The potential for clinical trials to impact patient care may be limited if the outcomes reported vary by trial and lack direct relevance to patients. We aimed to systematically assess the scope and consistency of outcomes reported in randomised trials of interventions for children with osteogenesis imperfecta.Methods: We systematically searched for all published and unpublished randomised trials of interventions for children with osteogenesis ...

ba0001oc5.5 | Treatment of osteoporosis | ECTS2013

Bone anabolic efficacy and safety of ba058, a novel analog of hPTHrP: 12-month extension data from a phase 2 clinical trial in postmenopausal women with osteoporosis

Hattersley Gary , Bilezikian John , Guerriero Jonathan , Kumar Prasanna , Zanchetta Jose , Lyttle C Richard , O'Dea Louis Saint L

A randomized, placebo-controlled phase 2 study evaluated the safety and efficacy of BA058, an analog of hPTHrP(1–34), in postmenopausal women with severe osteoporosis. 221 patients were randomized to received BA058 20, 40, and 80 μg, placebo or teriparatide (TP) 20 μg, by daily s.c. injection. 184 (83%) patients completed an initial 24 weeks of treatment. The mean percent change in lumbar spine BMD at 24 weeks was 1.6% with placebo, 6.7% with BA058 80 μg, a...

ba0001pp453 | Osteoporosis: treatment | ECTS2013

Factors influencing levels of bone resorption during denosumab dosing

Eastell Richard , Siris Ethel , Roux Christian , Black Dennis M. , Franchimont Nathalie , Jang Graham , Daizadeh Nadia , Wagman Rachel B. , Austin Matt

Denosumab treatment is associated with low fracture incidence, sustained BMD increases, and reduced sCTX. The decrease in median sCTX is at the quantifiable limit (0.049 ng/ml) one month post-dose, remains low, and attenuates at the end of the 6-month dosing interval. Using 7 years of data from the FREEDOM study and its extension, we characterized changes in sCTX over time and the influencing factors. In the bone turnover marker and pharmacokinetic substudies, serum was collec...

ba0003pp137 | Cell biology: osteoblasts and bone formation | ECTS2014

IGF1 stimulates protein synthesis by enhancing mRNA translation rate in osteoblasts

Bakker Astrid D. , Gakes Tom , Juffer Petra , Hogervorst Jolanda M.A. , de Wit Gerard M.J. , Klein-Nulend Jenneke , Jaspers Richard T.

IGF1 is an osteo-anabolic factor that stimulates osteogenic precursor cell differentiation. IGF1 is produced in bone in response to mechanical stimulation, but also in mechanically-stimulated muscle cells. IGF1 enhances the rate of mRNA translation in muscle cells via activation of the PI3K/AKT/mTOR pathway, thereby increasing in muscle mass. Therefore we hypothesized that IGF1 not just enhances osteogenic differentiation of precursors, but also stimulates protein syn...